Ribo's globally first-in-class FXI-targeting siRNA drug, vortosiran, received implied approval for a Phase I clinical trial in China, advancing coordinated development across China and Europe and its global multicenter clinical program.

Ozisiran Delivers Sustained Viral and Antigen Suppression in Chronic Hepatitis D - Preliminary Interim Phase IIa Results

Ribo announced the successful submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for RBD3133, a novel siRNA therapeutic targeting INHBE (inhibin subunit beta E), with overweight and obesity as its intended future therapeutic indications.

Ribo Presented New Data Highlighting Triglycerides, ApoC3 and Cardiovascular Health at ESC 2026

Ribo Discloses Positive Data from Vortosiran Phase IIa Trial - World’s First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease

Ribo will present at the inaugural CPIC on July 22, where it will disclose for the first time Phase IIa clinical data of vortosiran (RBD4059) for CAD.